In reviewing the presentation again something became apparent that I hadn't seen before, it was entirely based on U.S. product use. All references were to State's, not Countries, and nearly all the language had to do with using the products here.
I know the U.S. is considered the Gold Standard for drug approvals, and that on a per ca pita basis we spend far more than any other nation, however the rest of the world still represents about 70% of the marketplace, it shouldn't be ignored.
The presentation fails to mention Mediq, Emelia, etc. Is it because they aren't part of the plan for the U.S.
If this presentation was developed just for the discussion of U.S. application of their products it ought to state that. I would like to see a corporate presentation that took a worldwide view. I believe that clinical trials as currently envisioned are being done in Israel, I'm guessing it's because they can do them at much lower prices there. When it comes to eventual U.S. approval, I believe the trials will need to at least be international, with some of the clinics located in the U.S., the cost will be dramatically higher.
Gary
I know the U.S. is considered the Gold Standard for drug approvals, and that on a per ca pita basis we spend far more than any other nation, however the rest of the world still represents about 70% of the marketplace, it shouldn't be ignored.
The presentation fails to mention Mediq, Emelia, etc. Is it because they aren't part of the plan for the U.S.
If this presentation was developed just for the discussion of U.S. application of their products it ought to state that. I would like to see a corporate presentation that took a worldwide view. I believe that clinical trials as currently envisioned are being done in Israel, I'm guessing it's because they can do them at much lower prices there. When it comes to eventual U.S. approval, I believe the trials will need to at least be international, with some of the clinics located in the U.S., the cost will be dramatically higher.
Gary
